New stomach drug may protect heart patients from dangerous bleeding
NCT ID NCT07479056
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests if fexuprazan can prevent upper stomach bleeding in 400 heart patients at high risk for bleeding who must take two blood thinners after getting a heart stent. Participants receive either fexuprazan or the standard drug lansoprazole daily for 6 months. The goal is to see which drug better prevents bleeding, ulcers, and other stomach issues.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE CORONARY SYNDROMES (ACS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Catholic University of Korea, Eunpyeong St. Mary's Hospital
RECRUITINGSeoul, Eunpyeong-gu, 03312, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we predict which heart blockages will worsen after stenting?
- Can a drop of blood predict disease years before it strikes?
- Can a new catheter make heart stenting safer and more effective?
- Heart rehab goes hybrid: can a mix of home and clinic sessions boost adherence?
- Heart rehab may tweak cell death pathways — a study investigates
- Can a trained eye match ultrasound for heart stent placement?